{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:22:24Z","timestamp":1787714544183,"version":"build-2784847793"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Doc Ophthalmol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This report summarises the Clinical Endpoints Special Session held during the 62nd annual symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV), convened at Tivoli Vredenburg, Utrecht, The Netherlands. The session brought together clinicians, regulators, industry representatives, and a patient voice to consider the state of clinical endpoints in trials for inherited retinal disorders (IRDs). Discussions covered the adequacy of current endpoints, challenges of disease heterogeneity, regulatory expectations, operational feasibility, and the perspectives of patients. The session highlighted the need to anchor emerging endpoints to clinically meaningful outcomes and to minimise assessment burdens.<\/jats:p>","DOI":"10.1007\/s10633-026-10108-8","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:57:59Z","timestamp":1779299879000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical endpoints special session, ISCEV 2025, Utrecht"],"prefix":"10.1007","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0855-9533","authenticated-orcid":false,"given":"R.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-2897","authenticated-orcid":false,"given":"D.","family":"Birch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-911X","authenticated-orcid":false,"given":"K.","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4248-0033","authenticated-orcid":false,"given":"K.","family":"Fujinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8725-4051","authenticated-orcid":false,"given":"K.","family":"Holopigian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-6795","authenticated-orcid":false,"given":"C. J. F.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4889-5953","authenticated-orcid":false,"given":"J.","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1192-3487","authenticated-orcid":false,"given":"J. J.","family":"McAnany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-0905","authenticated-orcid":false,"given":"A. V.","family":"Cideciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-8397","authenticated-orcid":false,"given":"M. M.","family":"van Genderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"10097","key":"10108_CR1","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A et al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. The Lancet 390(10097):849\u2013860","journal-title":"The Lancet"},{"issue":"18","key":"10108_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13185512","volume":"13","author":"JM Igoe","year":"2024","unstructured":"Igoe JM, Lam BL, Gregori NZ (2024) Update on clinical trial endpoints in gene therapy trials for inherited retinal diseases. J Clin Med 13(18):5512","journal-title":"J Clin Med"},{"key":"10108_CR3","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016 [cited 2025 Nov 26]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/"},{"issue":"8","key":"10108_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40629-024-00312-w","volume":"33","author":"H Zander","year":"2024","unstructured":"Zander H, Engelbergs J (2024) Requirements for regulatory acceptance of biomarkers. Allergo J Int 33(8):309\u2013312","journal-title":"Allergo J Int"},{"issue":"6","key":"10108_CR5","doi-asserted-by":"publisher","first-page":"BIO27","DOI":"10.1167\/iovs.17-21778","volume":"58","author":"K Wickstr\u00f6m","year":"2017","unstructured":"Wickstr\u00f6m K, Moseley J (2017) Biomarkers and surrogate endpoints in drug development: a European regulatory view. Invest Ophthalmol Vis Sci 58(6):BIO27-33","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"10108_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1167\/iovs.62.14.30","volume":"62","author":"LA Levin","year":"2021","unstructured":"Levin LA, Sengupta M, Balcer LJ, Kupersmith MJ, Miller NR (2021) Report from the national eye institute workshop on neuro-ophthalmic disease clinical trial endpoints: optic neuropathies. Invest Ophthalmol Vis Sci 62(14):30","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10108_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1167\/tvst.14.3.25","volume":"14","author":"A Yaghy","year":"2025","unstructured":"Yaghy A, Birch DG, Hwang Y, Luo E, Jung J, Curtiss D et al (2025) Addressing multiplicity in retinal sensitivity analysis: an alternative approach to assessing gene therapy efficacy in inherited retinal diseases. Transl Vis Sci Technol 14(3):25","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"10108_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/ceo.13022","volume":"46","author":"DC Chung","year":"2018","unstructured":"Chung DC, McCague S, Yu ZF, Thill S, DiStefano-Pappas J, Bennett J et al (2018) Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol 46(3):247\u2013259","journal-title":"Clin Exp Ophthalmol"},{"key":"10108_CR9","unstructured":"jCyte, Inc. A prospective, multicenter, randomized study of the safety and efficacy of intravitreal injection of human retinal progenitor cells (jCell) in adult subjects with retinitis pigmentosa (RP) [Internet]. clinicaltrials.gov; 2024 June [cited 2025 Nov 26]. Report No.: NCT03073733. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03073733"},{"key":"10108_CR10","unstructured":"Center for Biologics Evaluation and Research. Human Gene Therapy for Retinal Disorders: Guidance for Industry [Internet]. FDA; 2024 [cited 2025 Oct 9]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-retinal-disorders"},{"issue":"8","key":"10108_CR11","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.8.25","volume":"9","author":"LN Ayton","year":"2020","unstructured":"Ayton LN, Rizzo JF, Bailey IL, Colenbrander A, Dagnelie G, Geruschat DR et al (2020) Harmonization of outcomes and vision endpoints in vision restoration trials: recommendations from the International HOVER taskforce. Transl Vis Sci Technol 9(8):25","journal-title":"Transl Vis Sci Technol"},{"issue":"9","key":"10108_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104095","volume":"29","author":"BP Leroy","year":"2024","unstructured":"Leroy BP, Daly A, H\u00e9on E, Sahel JA, Dollfus H (2024) Therapies for inherited retinal dystrophies: What is enough? Drug Discov Today 29(9):104095","journal-title":"Drug Discov Today"},{"issue":"97","key":"10108_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101160","volume":"1","author":"L Schmetterer","year":"2023","unstructured":"Schmetterer L, Scholl H, Garh\u00f6fer G, Janeschitz-Kriegl L, Corvi F, Sadda SR et al (2023) Endpoints for clinical trials in ophthalmology. Prog Retin Eye Res 1(97):101160","journal-title":"Prog Retin Eye Res"},{"issue":"23","key":"10108_CR14","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1001\/jama.2024.20358","volume":"332","author":"CK Shore","year":"2024","unstructured":"Shore CK, Worku TL, Kahn J (2024) Rare disease innovation at the FDA\u2014opportunities for implementation. JAMA 332(23):1973\u20131974","journal-title":"JAMA"},{"key":"10108_CR15","unstructured":"Center for Biologics Evaluation and Research. Cellular, Tissue, and Gene Therapies Advisory Committee - June 29 2011 Meeting Materials [Internet]. Center for Biologics Evaluation and Research; 2011 June [cited 2025 Nov 26]. Available from: https:\/\/wayback.archive-it.org\/7993\/20170111173922\/http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/CellularTissueandGeneTherapiesAdvisoryCommittee\/ucm249846.htm"},{"key":"10108_CR16","unstructured":"Assessing Novel Efficacy Endpoints in Ophthalmologic Rare Disease Drug and Biologics Development [Internet]. [cited 2025 Oct 9]. Available from: https:\/\/healthpolicy.duke.edu\/events\/assessing-novel-efficacy-endpoints-ophthalmologic-rare-disease-drug-and-biologics"},{"issue":"1","key":"10108_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10633-020-09812-w","volume":"142","author":"MB Hoffmann","year":"2021","unstructured":"Hoffmann MB, Bach M, Kondo M, Li S, Walker S, Holopigian K et al (2021) ISCEV standard for clinical multifocal electroretinography (mfERG) (2021 update). Doc Ophthalmol 142(1):5\u201316","journal-title":"Doc Ophthalmol"},{"issue":"3","key":"10108_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10633-022-09872-0","volume":"144","author":"AG Robson","year":"2022","unstructured":"Robson AG, Frishman LJ, Grigg J, Hamilton R, Jeffrey BG, Kondo M et al (2022) ISCEV standard for full-field clinical electroretinography (2022 update). Doc Ophthalmol 144(3):165\u2013177","journal-title":"Doc Ophthalmol"},{"issue":"1","key":"10108_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-017-9573-2","volume":"134","author":"PA Constable","year":"2017","unstructured":"Constable PA, Bach M, Frishman LJ, Jeffrey BG, Robson AG, International Society for Clinical Electrophysiology of Vision (2017) ISCEV standard for clinical electro-oculography (2017 update). Doc Ophthalmol 134(1):1\u20139","journal-title":"Doc Ophthalmol"},{"issue":"2","key":"10108_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10633-024-09970-1","volume":"148","author":"DA Thompson","year":"2024","unstructured":"Thompson DA, Bach M, McAnany JJ, \u0160u\u0161tar Habjan M, Viswanathan S, Robson AG (2024) ISCEV standard for clinical pattern electroretinography (2024 update). Doc Ophthalmol 148(2):75\u201385","journal-title":"Doc Ophthalmol"},{"issue":"2","key":"10108_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10633-025-10042-1","volume":"151","author":"M \u0160u\u0161tar Habjan","year":"2025","unstructured":"\u0160u\u0161tar Habjan M, Bach M, van Genderen MM, Li S, Mizota A, Nilsson J et al (2025) ISCEV standard for clinical visual evoked potentials (2025 update). Doc Ophthalmol 151(2):97\u2013112","journal-title":"Doc Ophthalmol"},{"issue":"1","key":"10108_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10633-023-09962-7","volume":"148","author":"JK Jolly","year":"2024","unstructured":"Jolly JK, Grigg JR, McKendrick AM, Fujinami K, Cideciyan AV, Thompson DA et al (2024) ISCEV and IPS guideline for the full-field stimulus test (FST). Doc Ophthalmol 148(1):3\u201314","journal-title":"Doc Ophthalmol"},{"issue":"7","key":"10108_CR23","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.7.2","volume":"9","author":"DA Thompson","year":"2020","unstructured":"Thompson DA, Iannaccone A, Ali RR, Arshavsky VY, Audo I, Bainbridge JWB et al (2020) Advancing clinical trials for inherited retinal diseases: recommendations from the second Monaciano symposium. Transl Vis Sci Technol 9(7):2","journal-title":"Transl Vis Sci Technol"},{"key":"10108_CR24","doi-asserted-by":"publisher","unstructured":"Biomarkers and surrogate endpoints in clinical trials - Fleming - 2012 - Statistics in Medicine - Wiley Online Library [Internet]. [cited 2025 Oct 9]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/sim.5403","DOI":"10.1002\/sim.5403"},{"issue":"5","key":"10108_CR25","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041312","volume":"13","author":"KZ Reape","year":"2023","unstructured":"Reape KZ, High KA (2023) Trial by \u201cFirsts\u201d: clinical trial design and regulatory considerations in the development and approval of the first AAV gene therapy product in the United States. Cold Spring Harb Perspect Med 13(5):a041312","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"10108_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/tvst.13.10.15","volume":"13","author":"MG Maguire","year":"2024","unstructured":"Maguire MG, Birch DG, Duncan JL, Ayala AR, Ayton LN, Cheetham JK et al (2024) Endpoints and design for clinical trials in USH2A-related retinal degeneration: results and recommendations from the RUSH2A natural history study. Trans Vis Sci Tech 13(10):15","journal-title":"Trans Vis Sci Tech"},{"key":"10108_CR27","unstructured":"European Medicines Agency. Multiplicity issues in clinical trials - Scientific guideline [Internet]. 2002 Sept [cited 2025 Nov 25]. Available from: https:\/\/www.ema.europa.eu\/en\/multiplicity-issues-clinical-trials-scientific-guideline"},{"key":"10108_CR28","unstructured":"European Medicines Agency. Investigation of subgroups in confirmatory clinical trials - Scientific guideline [Internet]. 2014 Feb [cited 2025 Nov 25]. Available from: https:\/\/www.ema.europa.eu\/en\/investigation-subgroups-confirmatory-clinical-trials-scientific-guideline"},{"issue":"2","key":"10108_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.5014\/ajot.2013.006015","volume":"67","author":"WJ Coster","year":"2013","unstructured":"Coster WJ (2013) Making the best match: selecting outcome measures for clinical trials and outcome studies. Am J Occup Ther 67(2):162\u2013170","journal-title":"Am J Occup Ther"},{"key":"10108_CR30","doi-asserted-by":"crossref","unstructured":"Fujinami K, Akiyama K, Tsunoda K, Ito S, Seko N, Yamamoto S (2025) Efficacy and safety of voretigene neparvovec in RPE65-retinopathy: Results of a phase III trial in Japan. Ophthalmology Science [Internet]. Nov 1 [cited 2025 Oct 10];5(6). Available from: https:\/\/www.ophthalmologyscience.org\/article\/S2666-9145(25)00174-5\/fulltext","DOI":"10.1016\/j.xops.2025.100876"},{"key":"10108_CR31","unstructured":"European Commission Public Health. Legal framework governing medicinal products for human use in the EU [Internet]. 2025 [cited 2025 Nov 25]. Available from: https:\/\/health.ec.europa.eu\/medicinal-products\/legal-framework-governing-medicinal-products-human-use-eu_en"},{"key":"10108_CR32","unstructured":"European Medicines Agency. ICH E8 General considerations for clinical studies - Scientific guideline [Internet]. 1998 Mar [cited 2025 Oct 13]. Available from: https:\/\/www.ema.europa.eu\/en\/ich-e8-general-considerations-clinical-studies-scientific-guideline"},{"key":"10108_CR33","unstructured":"European Medicines Agency. ICH E9 Statistical principles for clinical trials - Scientific guideline [Internet]. 1998 Sept [cited 2025 Oct 10]. Available from: https:\/\/www.ema.europa.eu\/en\/ich-e9-statistical-principles-clinical-trials-scientific-guideline"},{"issue":"7","key":"10108_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","volume":"125","author":"TR Fleming","year":"1996","unstructured":"Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125(7):605\u2013613","journal-title":"Ann Intern Med"},{"issue":"10411","key":"10108_CR35","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","volume":"402","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA et al (2023) Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. The Lancet 402(10411):1449\u20131458","journal-title":"The Lancet"},{"key":"10108_CR36","unstructured":"European Medicines Agency. Izelvay assessment report [Internet]. 2024 [cited 2025 Nov 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/withdrawal-report\/withdrawal-assessment-report-izelvay_en.pdf"},{"key":"10108_CR37","unstructured":"European Medicines Agency. Syfovre assessment report [Internet]. 2024 [cited 2025 Nov 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/syfovre-epar-refusal-public-assessment-report_en.pdf"},{"issue":"4","key":"10108_CR38","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/aos.17427","volume":"103","author":"JS Karuntu","year":"2025","unstructured":"Karuntu JS, Tulp SBAE, Boon CJF (2025) Relationship between the full\u2010field stimulus test and self\u2010reported visual function in patients with retinitis pigmentosa: REPEAT study report No. 3. Acta Ophthalmol 103(4):396\u2013403","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"10108_CR39","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/aos.16601","volume":"102","author":"JS Karuntu","year":"2024","unstructured":"Karuntu JS, Nguyen XT, Boon CJF (2024) Correlations between the michigan retinal degeneration questionnaire and visual function parameters in patients with retinitis pigmentosa. Acta Ophthalmol 102(5):555\u2013563","journal-title":"Acta Ophthalmol"},{"key":"10108_CR40","unstructured":"European Medicines Agency. Scientific advice and protocol assistance [Internet]. [cited 2025 Oct 13]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-advice-protocol-assistance"},{"key":"10108_CR41","unstructured":"European Medicines Agency. Qualification of novel methodologies for medicine development [Internet]. 2020 May [cited 2025 Oct 13]. Available from: https:\/\/www.ema.europa.eu\/en\/qualification-novel-methodologies-medicine-development"},{"key":"10108_CR42","unstructured":"FDA Center for Drug Evaluation and Research. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products \u2013 Guidance for Industry [Internet]. FDA; 2023 [cited 2026 Apr 02]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/formal-meetings-between-fda-and-sponsors-or-applicants-pdufa-products"},{"key":"10108_CR43","unstructured":"FDA Center for Drug Evaluation and Research. Patient-focused drug development: Incorporating clinical outcome assessments into endpoints for regulatory decision-making [Internet]. FDA; 2023 [cited 2025 Nov 26]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory"},{"issue":"1","key":"10108_CR44","doi-asserted-by":"publisher","first-page":"7438","DOI":"10.1038\/s41467-024-51575-4","volume":"15","author":"A Kvanta","year":"2024","unstructured":"Kvanta A, Rangaswamy N, Holopigian K, Watters C, Jennings N, Liew MSH et al (2024) Interim safety and efficacy of gene therapy for RLBP1-associated retinal dystrophy: a phase 1\/2 trial. Nat Commun 15(1):7438","journal-title":"Nat Commun"},{"key":"10108_CR45","doi-asserted-by":"publisher","first-page":"101115","DOI":"10.1016\/j.preteyeres.2022.101115","volume":"92","author":"K Stingl","year":"2023","unstructured":"Stingl K, Kempf M, Jung R, Kort\u00fcm F, Righetti G, Reith M et al (2023) Therapy with voretigene neparvovec How to measure success? Progress Retinal Eye Res 92:101115","journal-title":"Progress Retinal Eye Res"},{"issue":"11","key":"10108_CR46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/iovs.66.11.12","volume":"66","author":"DA Merle","year":"2025","unstructured":"Merle DA, Cuevas Villanueva V, Righetti G, Jung R, Kempf M, Kohl S et al (2025) Flavoprotein fluorescence imaging in Stargardt disease: linking metabolic stress to structural damage. Invest Ophthalmol Vis Sci 66(11):12","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10108_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","volume":"66","author":"SK Verbakel","year":"2018","unstructured":"Verbakel SK, van Huet RAC, Boon CJF, den Hollander AI, Collin RWJ, Klaver CCW et al (2018) Non-syndromic retinitis pigmentosa. Progress Retinal Eye Res 66:157\u2013186","journal-title":"Progress Retinal Eye Res"},{"key":"10108_CR48","unstructured":"European Medicines Agency. Guideline on the scientific application and the practical arrangements necessary to implement Regulation (EC) No 507\/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726\/2004 [Internet]. 2016 [cited 2025 Nov 25]. Available from: https:\/\/www.ema.europa.eu\/en\/guideline-scientific-application-practical-arrangements-necessary-implement-regulation-ec-no-507-2006-conditional-marketing-authorisation-medicinal-products-human-use-falling-within-scope-regulation"},{"key":"10108_CR49","unstructured":"European Medicines Agency. Marketing authorisation guidance documents [Internet]. 2016 [cited 2025 Nov 26]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-procedures-granting-marketing-authorisation-under-exceptional-circumstances-pursuant-article-14-8-regulation-ec-no-7262004_en.pdf"}],"container-title":["Documenta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-026-10108-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10633-026-10108-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-026-10108-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:32:57Z","timestamp":1787711577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10633-026-10108-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10108"],"URL":"https:\/\/doi.org\/10.1007\/s10633-026-10108-8","relation":{},"ISSN":["0012-4486","1573-2622"],"issn-type":[{"value":"0012-4486","type":"print"},{"value":"1573-2622","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DB financial support: AGTC\/Beacon, 4D MT, PYC Therapeutics, Ocugen. Consultant: Editas, 4D MT, PYC Therapeutics, ONL Therapeutics, Bluerock Therapeutics, Aldyra, SepulBio. Participates on Scientific Advisory Board for Nacuity Pharma. KF financial support: Paid consultant of Astellas Pharma Inc, Kubota Pharmaceutical Holdings Co., Ltd, and Acucela Inc., Novartis AG., Janssen Pharma., Saliogen therapeutics., Alnylam pharmaceuticals., FREST., Restore Vision., Takara Bio, AAVangrade, Santen Pharm, belite Bio, Staple Bio and Compass. Personal fees from Astellas Pharma Inc, Kubota Pharmaceutical Holdings Co., Ltd., Acucela Inc., SANTEN Company Limited, Foundation Fighting Blindness, Foundation Fighting Blindness Clinical Research  Institute, Japanese Ophthalmology Society, Japan Retinitis Pigmentosa Society. KH is an employee of Novartis Pharma AG, Biomedical Research, East Hanover, NJ, USA. KS is\/was consultant for Novartis, ProQR Therapeutics, ViGeneron, Santen, Janssen, Lundbeck, THEA, RhyGaze, Ascidian with all consultancy fees paid to University of T\u00fcbingen to support research. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not involve any studies on human participants conducted by the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study involved no research on human participants and consent is not applicable.","order":3,"name":"Ethics","label":"Statement of human rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study involved no research on animals.","order":4,"name":"Ethics","label":"Statement on the welfare of animals","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this article does not contain any studies with human participants performed directly by any of the authors, the concept of informed consent is not applicable.","order":5,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}